^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19 inhibitor

    Related drugs:
    17h
    A single-center retrospective study of short-term efficacy and safety of blinatumomab in the treatment of high-risk acute lymphoblastic leukemia. (PubMed, BMC Cancer)
    Blinatumomab achieved high short-term MRD response rates in high-risk B-ALL. Inferior outcomes appeared to be associated with the presence of BCR::ABL1 T315I mutations and E2A::PBX1 rearrangements.
    Retrospective data • Journal
    |
    ABL1 (ABL proto-oncogene 1) • PBX1 (PBX Homeobox 1)
    |
    ABL1 T315I
    |
    Blincyto (blinatumomab)
    22h
    A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2030 --> Apr 2031 | Trial primary completion date: Jan 2030 --> Jul 2030
    Trial completion date • Trial primary completion date
    1d
    Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting | Trial completion date: Jul 2027 --> Jan 2027
    Enrollment closed • Trial completion date
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • daunorubicin • Zynyz (retifanlimab-dlwr) • Rituxan Hycela (rituximab/hyaluronidase) • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq)
    1d
    A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) (clinicaltrials.gov)
    P2/3, N=960, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD)
    1d
    AAAV0505: A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=6, Enrolling by invitation, Hospital for Special Surgery, New York | Suspended --> Enrolling by invitation
    Enrollment open
    |
    cyclophosphamide • NKX019
    7d
    D7400C00006: A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=226, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 positive
    |
    surovatamig (AZD0486)
    8d
    Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Suspended, David Bond, MD | Recruiting --> Suspended
    Trial suspension
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    carboplatin • lenalidomide • cyclophosphamide • ifosfamide • etoposide IV • Monjuvi (tafasitamab-cxix)
    10d
    MK-1045-005: A clinical trial of MK-1045 in people with B-cell acute lymphoblastic leukemia (2025-522267-15-00)
    P2/3, N=36, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    Blincyto (blinatumomab) • Actemra IV (tocilizumab)
    12d
    Blinatumomab bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model. (PubMed, J Immunother Cancer)
    These findings provide preclinical proof-of-concept that BLINA and ABATA can be combined to uncouple GvL from GvHD. This strategy preserves CD28-independent T-cell cytotoxicity while limiting allo-reactivity, providing a strong rationale for investigating this combination in the post-transplant setting.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9) • LAMP1 (Lysosomal Associated Membrane Protein 1) • IL15 (Interleukin 15) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
    |
    Blincyto (blinatumomab) • Orencia (abatacept)
    13d
    Ph- ALL-2026: Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Venclexta (venetoclax) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine
    14d
    A clinical trial of MK-1045 and rituximab in people with follicular lymphoma (MK-1045-007) (2025-522777-10-00)
    P2/3, N=2, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • bendamustine • Truxima (rituximab-abbs) • Actemra IV (tocilizumab)
    15d
    Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, SWOG Cancer Research Network
    New P2 trial
    |
    CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A)
    |
    clonoSEQ®
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • Revuforj (revumenib) • leucovorin calcium • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)